PharmaFluidics acquired by Thermo Fisher Scientific

Nov 09, 2021 | Katleen Vandersmissen
HERAN Partners is pleased to announce that their portfolio company PharmaFluidics has been acquired by Thermo Fisher Scientific. Following the sale of BlueBee to Illumina in 2020, PharmaFluidics is the second exit for HERAN HealthTech Fund I.

Press release:

PHILADELPHIA, Nov. 1, 2021 /PRNewswire
Thermo Fisher Scientific, the world leader in serving science,  announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns.

The µPAC portfolio of columns enhance liquid chromatography (LC) performance in biomarker, proteomics and drug research and development applications, helping biotechnology and pharmaceutical companies uncover new insights and advance scientific discovery. Through an innovative approach, separation performance and sensitivity are improved with the μPAC chromatography columns, allowing for the identification of substantially more compounds in complex biological samples. The μPAC portfolio acquisition complements Thermo Fisher's existing chromatography solutions to deliver extended analytical capabilities to researchers.

The μPAC columns deliver excellent separation and sensitivity to achieve greater identifications from samples with a large dynamic range, ultimately enhancing the solutions available for pharmaceutical laboratories to help meet changing needs in medical research.

"LC is a key analytical technique across numerous applications, and its accuracy, reproducibility and robustness is critical to the delivery of meaningful results. Columns are an essential part of these workflows, and the next-generation μPAC columns push this element to a new level through innovative pillar array technology, improving the quality of data."

Kent Davidson - VP and General Manager, high performance chromatography solutions, Thermo Fisher Scientific

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Their mission is to enable their customers to make the world healthier,cleaner and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories. The global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through their industry-leading brands, including Thermo Scientific,Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Press release ThermoFisher

About PharmaFluidics

Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility and robustness. PharmaFluidics was founded in 2010 as a spin-off from the University of Brussels (VUB). The first external funding was raised in 2014, followed by additional capital increases in 2016 and 2018 from experienced venture capital investors. Sales of the µPACTM columns were launched in 2017, and the company continued to build its portfolio based on the pillar array technology.  In November 2021, Thermo Fisher Scientific announced the acquisition of Pharmafluidics. For more information, please visit www.pharmafluidics.com

Join a Heran Fund

We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pitch your company

Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.